BioScrip To Pay Shareholders $11M In Exjade Fallout
By Dani Kass ( February 12, 2016, 2:32 PM EST) -- A New York federal judge on Thursday preliminarily signed off on a $10.9 million agreement between BioScrip Inc. and a class of shareholders to settle claims that stock prices fell because the company failed to disclose Anti-Kickback Statute and False Claims Act violations tied to Novartis' iron-reducing drug Exjade....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.